Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization

Early intensification with methotrexate (MTX) is a key component of acute lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX intensification exist but had not been compared in T-cell ALL (T-ALL): the Children's Oncology Group (COG) escalating dose intravenous MTX without leuc...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 36; no. 29; pp. 2926 - 2934
Main Authors Winter, Stuart S, Dunsmore, Kimberly P, Devidas, Meenakshi, Wood, Brent L, Esiashvili, Natia, Chen, Zhiguo, Eisenberg, Nancy, Briegel, Nikki, Hayashi, Robert J, Gastier-Foster, Julie M, Carroll, Andrew J, Heerema, Nyla A, Asselin, Barbara L, Gaynon, Paul S, Borowitz, Michael J, Loh, Mignon L, Rabin, Karen R, Raetz, Elizabeth A, Zweidler-Mckay, Patrick A, Winick, Naomi J, Carroll, William L, Hunger, Stephen P
Format Journal Article
LanguageEnglish
Published United States American Society of Clinical Oncology 10.10.2018
Subjects
Adolescent
Adult
Antimetabolites, Antineoplastic - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Asparaginase - administration & dosage
Child
Child, Preschool
Disease-Free Survival
Female
Humans
Infant
Leucovorin - administration & dosage
Male
Methotrexate - administration & dosage
ORIGINAL REPORTS
Polyethylene Glycols - administration & dosage
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - mortality
Young Adult
Online AccessGet full text

Cover

Abstract Early intensification with methotrexate (MTX) is a key component of acute lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX intensification exist but had not been compared in T-cell ALL (T-ALL): the Children's Oncology Group (COG) escalating dose intravenous MTX without leucovorin rescue plus pegaspargase escalating dose, Capizzi-style, intravenous MTX (C-MTX) regimen and the Berlin-Frankfurt-Muenster (BFM) high-dose intravenous MTX (HDMTX) plus leucovorin rescue regimen. COG AALL0434 included a 2 × 2 randomization that compared the COG-augmented BFM (ABFM) regimen with either C-MTX or HDMTX during the 8-week interim maintenance phase. All patients with T-ALL, except for those with low-risk features, received prophylactic (12 Gy) or therapeutic (18 Gy for CNS3) cranial irradiation during either the consolidation (C-MTX; second month of therapy) or delayed intensification (HDMTX; seventh month of therapy) phase. AALL0434 accrued 1,895 patients from 2007 to 2014. The 5-year event-free survival and overall survival rates for all eligible, evaluable patients with T-ALL were 83.8% (95% CI, 81.2% to 86.4%) and 89.5% (95% CI, 87.4% to 91.7%), respectively. The 1,031 patients with T-ALL but without CNS3 disease or testicular leukemia were randomly assigned to receive ABFM with C-MTX (n = 519) or HDMTX (n = 512). The estimated 5-year disease-free survival ( P = .005) and overall survival ( P = .04) rates were 91.5% (95% CI, 88.1% to 94.8%) and 93.7% (95% CI, 90.8% to 96.6%) for C-MTX and 85.3% (95% CI, 81.0%-89.5%) and 89.4% (95% CI, 85.7%-93.2%) for HDMTX. Patients assigned to C-MTX had 32 relapses, six with CNS involvement, whereas those assigned to HDMTX had 59 relapses, 23 with CNS involvement. AALL0434 established that ABFM with C-MTX was superior to ABFM plus HDMTX for T-ALL in approximately 90% of patients who received CRT, with later timing for those receiving HDMTX.
AbstractList PURPOSEEarly intensification with methotrexate (MTX) is a key component of acute lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX intensification exist but had not been compared in T-cell ALL (T-ALL): the Children's Oncology Group (COG) escalating dose intravenous MTX without leucovorin rescue plus pegaspargase escalating dose, Capizzi-style, intravenous MTX (C-MTX) regimen and the Berlin-Frankfurt-Muenster (BFM) high-dose intravenous MTX (HDMTX) plus leucovorin rescue regimen. PATIENTS AND METHODSCOG AALL0434 included a 2 × 2 randomization that compared the COG-augmented BFM (ABFM) regimen with either C-MTX or HDMTX during the 8-week interim maintenance phase. All patients with T-ALL, except for those with low-risk features, received prophylactic (12 Gy) or therapeutic (18 Gy for CNS3) cranial irradiation during either the consolidation (C-MTX; second month of therapy) or delayed intensification (HDMTX; seventh month of therapy) phase. RESULTSAALL0434 accrued 1,895 patients from 2007 to 2014. The 5-year event-free survival and overall survival rates for all eligible, evaluable patients with T-ALL were 83.8% (95% CI, 81.2% to 86.4%) and 89.5% (95% CI, 87.4% to 91.7%), respectively. The 1,031 patients with T-ALL but without CNS3 disease or testicular leukemia were randomly assigned to receive ABFM with C-MTX (n = 519) or HDMTX (n = 512). The estimated 5-year disease-free survival ( P = .005) and overall survival ( P = .04) rates were 91.5% (95% CI, 88.1% to 94.8%) and 93.7% (95% CI, 90.8% to 96.6%) for C-MTX and 85.3% (95% CI, 81.0%-89.5%) and 89.4% (95% CI, 85.7%-93.2%) for HDMTX. Patients assigned to C-MTX had 32 relapses, six with CNS involvement, whereas those assigned to HDMTX had 59 relapses, 23 with CNS involvement. CONCLUSIONAALL0434 established that ABFM with C-MTX was superior to ABFM plus HDMTX for T-ALL in approximately 90% of patients who received CRT, with later timing for those receiving HDMTX.
Early intensification with methotrexate (MTX) is a key component of acute lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX intensification exist but had not been compared in T-cell ALL (T-ALL): the Children's Oncology Group (COG) escalating dose intravenous MTX without leucovorin rescue plus pegaspargase escalating dose, Capizzi-style, intravenous MTX (C-MTX) regimen and the Berlin-Frankfurt-Muenster (BFM) high-dose intravenous MTX (HDMTX) plus leucovorin rescue regimen. COG AALL0434 included a 2 × 2 randomization that compared the COG-augmented BFM (ABFM) regimen with either C-MTX or HDMTX during the 8-week interim maintenance phase. All patients with T-ALL, except for those with low-risk features, received prophylactic (12 Gy) or therapeutic (18 Gy for CNS3) cranial irradiation during either the consolidation (C-MTX; second month of therapy) or delayed intensification (HDMTX; seventh month of therapy) phase. AALL0434 accrued 1,895 patients from 2007 to 2014. The 5-year event-free survival and overall survival rates for all eligible, evaluable patients with T-ALL were 83.8% (95% CI, 81.2% to 86.4%) and 89.5% (95% CI, 87.4% to 91.7%), respectively. The 1,031 patients with T-ALL but without CNS3 disease or testicular leukemia were randomly assigned to receive ABFM with C-MTX (n = 519) or HDMTX (n = 512). The estimated 5-year disease-free survival ( P = .005) and overall survival ( P = .04) rates were 91.5% (95% CI, 88.1% to 94.8%) and 93.7% (95% CI, 90.8% to 96.6%) for C-MTX and 85.3% (95% CI, 81.0%-89.5%) and 89.4% (95% CI, 85.7%-93.2%) for HDMTX. Patients assigned to C-MTX had 32 relapses, six with CNS involvement, whereas those assigned to HDMTX had 59 relapses, 23 with CNS involvement. AALL0434 established that ABFM with C-MTX was superior to ABFM plus HDMTX for T-ALL in approximately 90% of patients who received CRT, with later timing for those receiving HDMTX.
Author Winick, Naomi J
Devidas, Meenakshi
Winter, Stuart S
Zweidler-Mckay, Patrick A
Heerema, Nyla A
Raetz, Elizabeth A
Gastier-Foster, Julie M
Chen, Zhiguo
Dunsmore, Kimberly P
Briegel, Nikki
Hayashi, Robert J
Gaynon, Paul S
Carroll, Andrew J
Rabin, Karen R
Wood, Brent L
Esiashvili, Natia
Loh, Mignon L
Asselin, Barbara L
Hunger, Stephen P
Eisenberg, Nancy
Borowitz, Michael J
Carroll, William L
Author_xml – sequence: 1
  givenname: Stuart S
  surname: Winter
  fullname: Winter, Stuart S
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 2
  givenname: Kimberly P
  surname: Dunsmore
  fullname: Dunsmore, Kimberly P
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 3
  givenname: Meenakshi
  surname: Devidas
  fullname: Devidas, Meenakshi
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 4
  givenname: Brent L
  surname: Wood
  fullname: Wood, Brent L
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 5
  givenname: Natia
  surname: Esiashvili
  fullname: Esiashvili, Natia
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 6
  givenname: Zhiguo
  surname: Chen
  fullname: Chen, Zhiguo
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 7
  givenname: Nancy
  surname: Eisenberg
  fullname: Eisenberg, Nancy
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 8
  givenname: Nikki
  surname: Briegel
  fullname: Briegel, Nikki
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 9
  givenname: Robert J
  surname: Hayashi
  fullname: Hayashi, Robert J
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 10
  givenname: Julie M
  surname: Gastier-Foster
  fullname: Gastier-Foster, Julie M
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 11
  givenname: Andrew J
  surname: Carroll
  fullname: Carroll, Andrew J
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 12
  givenname: Nyla A
  surname: Heerema
  fullname: Heerema, Nyla A
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 13
  givenname: Barbara L
  surname: Asselin
  fullname: Asselin, Barbara L
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 14
  givenname: Paul S
  surname: Gaynon
  fullname: Gaynon, Paul S
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 15
  givenname: Michael J
  surname: Borowitz
  fullname: Borowitz, Michael J
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 16
  givenname: Mignon L
  surname: Loh
  fullname: Loh, Mignon L
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 17
  givenname: Karen R
  surname: Rabin
  fullname: Rabin, Karen R
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 18
  givenname: Elizabeth A
  surname: Raetz
  fullname: Raetz, Elizabeth A
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 19
  givenname: Patrick A
  surname: Zweidler-Mckay
  fullname: Zweidler-Mckay, Patrick A
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 20
  givenname: Naomi J
  surname: Winick
  fullname: Winick, Naomi J
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 21
  givenname: William L
  surname: Carroll
  fullname: Carroll, William L
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
– sequence: 22
  givenname: Stephen P
  surname: Hunger
  fullname: Hunger, Stephen P
  organization: Stuart S. Winter, Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN; Kimberly P. Dunsmore, Carilion Clinic, Roanoke, VA; Meenakshi Devidas and Zhiguo Chen, University of Florida, Gainesville, FL; Brent L. Wood, Seattle Children's Hospital, Seattle, WA; Natia Esiashvili, Emory University, Atlanta, GA; Nancy Eisenberg, University of New Mexico Health Sciences Center, Albuquerque, NM; Nikki Briegel, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Robert J. Hayashi, St Louis Children's Hospital, St Louis, MO; Julie M. Gastier-Foster, Nationwide Children's Hospital; Julie M. Gastier-Foster and Nyla A. Heerema, Ohio State University, Columbus, OH; Andrew J. Carroll, University of Alabama at Birmingham, Birmingham, AL; Barbara L. Asselin, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester; Elizabeth A. Raetz and William L. Carroll, Perlmutter Cancer Center at NYU Langone Health, New York, NY; Paul S. Gaynon, Children's Hospital of Los Angeles, Los Angeles; Mignon L. Loh, University of California, San Francisco, San Francisco, CA; Michael J. Borowitz, Johns Hopkins University, Baltimore, MD; Karen R. Rabin, Baylor College of Medicine, Houston; Naomi J. Winick, University of Texas Southwestern, Dallas, TX; Patrick A. Zweidler-Mckay, ImmunoGen, Waltham, MA; and Stephen P. Hunger, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30138085$$D View this record in MEDLINE/PubMed
BookMark eNpVkUtvEzEQxy1URNPAnRPyDS4b_Fp7ywFpFdEHWhSpFAEny_FOsoZdO9jeiPQr8SVJaIngNIf5P0bzO0MnPnhA6DklM8oIef1-vpgxQquZUjPFSvIITWjJVKFUWZ6gCVGcFbTiX07RWUrfCKGi4uUTdMoJ5RWpygn6dT1sYthCiz-Oceu2pserEPG8c30bwWPjW_w1jH6N63bsc8KfXe7wbdE4D2YNuLZjBtzshk0Xlr1J2VncwPgdBmfe4BtIf0wXMQw4d3DMfZnwwtvQh_UOX8YwbnBdNw0RXOAPkLuQI_w0--CbfX8Y3J3JLvin6PHK9AmePcwp-nTx7nZ-VTSLy-t53RRWCJ6LUjLKWGWsNJYpWy3BMmi5XUkpODXnwqyMAiJbodqKWc4PQiFBwlKIVhg-RW_vczfjcoDWgs_R9HoT3WDiTgfj9P8b7zq9DlstuZSH107Rq4eAGH6MkLIeXLLQ98ZDGJNm5JxzymVZ7qXkXmpjSCnC6lhDiT4w1nvG-sBYK6UPjPeWF_-edzT8hcp_AzVtp-8
CitedBy_id crossref_primary_10_1002_cncr_34150
crossref_primary_10_1044_2023_AJA_22_00157
crossref_primary_10_17650_1818_8346_2023_18_4_135_144
crossref_primary_10_3389_fimmu_2024_1333037
crossref_primary_10_1182_blood_2019004043
crossref_primary_10_1038_s41467_022_32092_8
crossref_primary_10_3390_jcm10204728
crossref_primary_10_1136_jitc_2020_002026
crossref_primary_10_1080_10428194_2019_1668941
crossref_primary_10_1182_blood_2022018653
crossref_primary_10_1007_s40272_021_00463_1
crossref_primary_10_3390_cancers16040723
crossref_primary_10_1002_acg2_70
crossref_primary_10_1002_JLB_5MA1121_644R
crossref_primary_10_1002_pbc_29457
crossref_primary_10_1007_s11899_019_00501_3
crossref_primary_10_1016_j_clml_2022_07_010
crossref_primary_10_1080_10428194_2022_2102621
crossref_primary_10_1016_j_beha_2023_101519
crossref_primary_10_1038_s41401_023_01108_4
crossref_primary_10_6004_jnccn_2021_0042
crossref_primary_10_1016_j_yao_2024_02_007
crossref_primary_10_1016_j_jtct_2022_05_037
crossref_primary_10_1097_MPH_0000000000002787
crossref_primary_10_1182_blood_2023020678
crossref_primary_10_1002_cncr_33609
crossref_primary_10_1182_blood_2022017035
crossref_primary_10_3389_fonc_2021_797194
crossref_primary_10_1200_JCO_21_02678
crossref_primary_10_1073_pnas_2118529119
crossref_primary_10_1002_pbc_28475
crossref_primary_10_1038_s41375_022_01590_5
crossref_primary_10_1182_bloodadvances_2021004334
crossref_primary_10_1016_j_phoj_2020_03_001
crossref_primary_10_3390_cancers14081873
crossref_primary_10_1182_hematology_2019000009
crossref_primary_10_1177_2040620720903531
crossref_primary_10_1038_s41375_024_02277_9
crossref_primary_10_3390_cancers13092108
crossref_primary_10_1016_S1470_2045_21_00328_4
crossref_primary_10_1016_j_clml_2023_03_013
crossref_primary_10_1097_MOP_0000000000001316
crossref_primary_10_1007_s11864_020_00757_5
crossref_primary_10_1111_cas_14021
crossref_primary_10_2147_BLCTT_S342052
crossref_primary_10_3389_fonc_2020_01550
crossref_primary_10_3389_fonc_2022_841179
crossref_primary_10_15264_cpho_2019_26_1_12
crossref_primary_10_1101_cshperspect_a035246
crossref_primary_10_1021_acsbiomaterials_2c01329
crossref_primary_10_4143_crt_2020_507
crossref_primary_10_3390_cancers14246142
crossref_primary_10_1200_JCO_19_03141
crossref_primary_10_1002_pbc_27915
crossref_primary_10_3390_cancers12020333
crossref_primary_10_1038_s41592_020_0748_5
crossref_primary_10_3390_cancers14082021
crossref_primary_10_1038_s41408_020_00383_2
crossref_primary_10_1007_s12185_023_03626_7
crossref_primary_10_1021_acsami_3c16839
crossref_primary_10_1177_2040620720929475
crossref_primary_10_1016_S2152_2650_21_01225_8
crossref_primary_10_1002_pbc_29141
crossref_primary_10_3390_lymphatics1010005
crossref_primary_10_1002_pbc_29263
crossref_primary_10_1007_s11684_020_0759_8
crossref_primary_10_1007_s12098_023_04731_5
crossref_primary_10_3389_fonc_2019_00126
crossref_primary_10_1002_cncr_34646
crossref_primary_10_1016_j_taap_2024_116920
crossref_primary_10_1038_s41375_019_0422_z
crossref_primary_10_3389_fcell_2021_767510
crossref_primary_10_3324_haematol_2020_247031
crossref_primary_10_1186_s40780_022_00247_w
crossref_primary_10_1038_s41375_021_01243_z
crossref_primary_10_1182_bloodadvances_2020002700
crossref_primary_10_1016_j_beha_2023_101449
crossref_primary_10_1002_pbc_28719
crossref_primary_10_1080_1744666X_2020_1732819
crossref_primary_10_3322_caac_21665
crossref_primary_10_3389_fcell_2020_603837
crossref_primary_10_3390_ijms21207685
crossref_primary_10_3390_cancers13164068
crossref_primary_10_1038_s41467_022_28682_1
crossref_primary_10_1016_j_canep_2021_102040
crossref_primary_10_3389_fonc_2022_836452
crossref_primary_10_6004_jnccn_2020_0001
crossref_primary_10_1097_CM9_0000000000001999
crossref_primary_10_1200_JCO_20_00256
crossref_primary_10_1200_JCO_20_00531
crossref_primary_10_1038_s41375_019_0598_2
crossref_primary_10_1038_s41392_022_00898_z
crossref_primary_10_1200_JCO_20_03370
crossref_primary_10_1080_13543784_2023_2161361
crossref_primary_10_1016_S1470_2045_19_30031_2
crossref_primary_10_1038_s41588_022_01159_z
crossref_primary_10_1097_MPH_0000000000001926
crossref_primary_10_1200_JCO_22_01760
crossref_primary_10_1038_s41375_022_01714_x
crossref_primary_10_1166_mex_2022_2185
crossref_primary_10_1172_JCI141566
crossref_primary_10_1182_blood_2020008471
crossref_primary_10_3390_cancers14122886
crossref_primary_10_1080_14737140_2023_2271662
crossref_primary_10_3390_cancers14092169
crossref_primary_10_1002_pbc_30585
crossref_primary_10_1182_blood_2022019532
crossref_primary_10_1111_biom_13550
crossref_primary_10_1111_bjh_19381
crossref_primary_10_1016_S2352_3026_22_00371_4
crossref_primary_10_1016_j_ymthe_2021_07_001
crossref_primary_10_1080_19336918_2023_2191913
crossref_primary_10_1007_s12288_021_01502_0
crossref_primary_10_1016_j_yao_2021_02_014
crossref_primary_10_1182_blood_2019001557
crossref_primary_10_1182_bloodadvances_2023010303
crossref_primary_10_1080_10428194_2020_1791852
crossref_primary_10_1097_CCO_0000000000000900
crossref_primary_10_1182_hem_V21_1_2024115
crossref_primary_10_3390_ijms20215313
crossref_primary_10_1200_JCO_20_02973
crossref_primary_10_1002_sim_8557
crossref_primary_10_1146_annurev_cancerbio_043020_110055
crossref_primary_10_1038_s41388_020_01469_8
crossref_primary_10_1053_j_semdp_2023_10_001
crossref_primary_10_1186_s13045_019_0801_y
crossref_primary_10_1002_pbc_29238
crossref_primary_10_1007_s12098_023_04745_z
crossref_primary_10_1080_14656566_2022_2033725
crossref_primary_10_1186_s43046_022_00126_3
crossref_primary_10_1007_s00432_021_03551_4
crossref_primary_10_1080_13880209_2023_2168703
crossref_primary_10_24304_kjcp_2019_29_2_101
crossref_primary_10_1200_JCO_23_00088
crossref_primary_10_1038_s41409_021_01542_0
crossref_primary_10_1155_2021_5561860
crossref_primary_10_1111_bjh_15793
crossref_primary_10_1182_blood_2023023568
crossref_primary_10_1016_j_phoj_2024_06_004
crossref_primary_10_1016_j_ejca_2022_08_013
crossref_primary_10_1038_s41375_023_01900_5
crossref_primary_10_1002_pbc_30571
crossref_primary_10_1186_s12885_022_10072_x
crossref_primary_10_3390_biomedicines9111621
crossref_primary_10_1111_ejh_14006
crossref_primary_10_1186_s40164_022_00368_w
crossref_primary_10_1093_jnci_djz043
crossref_primary_10_1186_s13039_024_00682_4
Cites_doi 10.1182/blood.V99.12.4386
10.1038/leu.2016.60
10.1111/bjh.12882
10.1002/pbc.25470
10.1038/sj.leu.2401310
10.1002/cam4.1206
10.1182/blood-2007-10-117150
10.1200/JCO.2003.10.116
10.1200/JCO.2015.62.4544
10.1182/blood-2005-08-3482
10.1200/JCO.2010.28.3390
10.1182/blood.V84.2.564.564
10.1002/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4
10.1200/JCO.2011.40.8724
10.1158/1541-7786.MCR-13-0576
10.1016/j.ejca.2005.02.024
10.1111/j.1365-2141.2009.07853.x
10.1016/S1470-2045(09)70228-1
10.1200/JCO.2006.05.9055
10.1007/978-1-4615-4811-9_69
10.1007/978-1-62703-357-2_8
10.1038/bjc.1977.1
10.1056/NEJMoa0900386
10.1182/blood-2010-12-322909
10.1182/blood-2003-07-2577
10.1056/NEJMsa060185
10.1182/blood-2011-03-338707
10.1056/NEJMra1400972
10.1182/blood-2007-02-070342
10.1200/JCO.1998.16.4.1270
10.1200/JCO.2014.59.1636
10.1200/JCO.1998.16.3.920
10.1016/S1470-2045(08)70314-0
10.1016/S0140-6736(98)11079-6
10.1126/science.1102160
10.1111/bjh.12865
10.1182/blood-2015-09-670729
10.1200/JCO.1999.17.12.3745
10.1200/JCO.2005.03.426
10.1056/NEJM199806043382304
10.1080/10428194.2017.1397658
10.1200/JCO.1997.15.6.2222
10.1182/blood-2010-06-292615
10.1097/MOP.0000000000000171
10.1016/S0037-1963(03)00195-1
10.1038/leu.2009.262
10.1056/NEJMoa035091
10.1200/JCO.2011.37.8018
10.1200/JCO.1995.13.2.310
10.1182/blood-2017-04-778829
ContentType Journal Article
Copyright 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology
Copyright_xml – notice: 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1200/JCO.2018.77.7250
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Improved Survival for Patients With T-ALL
EISSN 1527-7755
EndPage 2934
ExternalDocumentID 10_1200_JCO_2018_77_7250
30138085
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA016058
– fundername: NCI NIH HHS
  grantid: U24 CA196173
– fundername: NCI NIH HHS
  grantid: U10 CA180899
– fundername: NCI NIH HHS
  grantid: U10 CA098413
– fundername: NCI NIH HHS
  grantid: U10 CA180886
– fundername: NCI NIH HHS
  grantid: U10 CA098543
GroupedDBID ---
.55
0R~
18M
2WC
34G
39C
4.4
53G
5GY
5RE
8F7
AAQQT
AARDX
AAWTL
AAYEP
AAYOK
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AWKKM
BAWUL
C45
CGR
CS3
CUY
CVF
DIK
EBS
ECM
EIF
EJD
F5P
F9R
FBNNL
FD8
GX1
H13
HZ~
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
NPM
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RLZ
RUC
SJN
SV3
TEORI
TR2
TWZ
UDS
VVN
WH7
X7M
YCJ
YFH
YQY
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c443t-5621228ac6ac27c8bec2ed3cf66431a94afa7e06d47d82c33c6ac46e6eb44d4a3
ISSN 0732-183X
IngestDate Tue Sep 17 21:24:12 EDT 2024
Fri Oct 25 04:21:32 EDT 2024
Fri Dec 06 05:14:14 EST 2024
Sat Sep 28 08:28:35 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 29
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c443t-5621228ac6ac27c8bec2ed3cf66431a94afa7e06d47d82c33c6ac46e6eb44d4a3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
S.S.W. and K.P.D. contributed equally as first authors.
N.J.W., W.L.C., and S.P.H. contributed equally as senior authors.
OpenAccessLink https://europepmc.org/articles/pmc6366301?pdf=render
PMID 30138085
PQID 2093313655
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6366301
proquest_miscellaneous_2093313655
crossref_primary_10_1200_JCO_2018_77_7250
pubmed_primary_30138085
PublicationCentury 2000
PublicationDate 2018-10-10
PublicationDateYYYYMMDD 2018-10-10
PublicationDate_xml – month: 10
  year: 2018
  text: 2018-10-10
  day: 10
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2018
Publisher American Society of Clinical Oncology
Publisher_xml – name: American Society of Clinical Oncology
References 30875487 - J Clin Oncol. 2019 Mar 20;37(9):761
B20
B21
B22
B23
B24
B25
B26
B27
B28
B29
Uckun FM (B3) 1998; 91
B30
B31
B32
B33
B34
B36
B37
B38
B39
B1
B2
B4
B5
B6
B7
B8
B9
B41
B42
B43
B44
B45
B46
B48
B49
B50
B51
B52
B53
B10
B54
B11
B55
B12
B14
B15
B16
B17
B18
B19
References_xml – ident: B6
  doi: 10.1182/blood.V99.12.4386
– ident: B26
  doi: 10.1038/leu.2016.60
– ident: B33
  doi: 10.1111/bjh.12882
– ident: B16
  doi: 10.1002/pbc.25470
– ident: B14
  doi: 10.1038/sj.leu.2401310
– ident: B38
  doi: 10.1002/cam4.1206
– ident: B49
  doi: 10.1182/blood-2007-10-117150
– ident: B50
  doi: 10.1200/JCO.2003.10.116
– ident: B17
  doi: 10.1200/JCO.2015.62.4544
– ident: B30
  doi: 10.1182/blood-2005-08-3482
– ident: B31
  doi: 10.1200/JCO.2010.28.3390
– ident: B18
  doi: 10.1182/blood.V84.2.564.564
– ident: B2
  doi: 10.1002/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4
– ident: B9
  doi: 10.1200/JCO.2011.40.8724
– ident: B43
  doi: 10.1158/1541-7786.MCR-13-0576
– ident: B21
  doi: 10.1016/j.ejca.2005.02.024
– ident: B54
  doi: 10.1111/j.1365-2141.2009.07853.x
– ident: B52
  doi: 10.1016/S1470-2045(09)70228-1
– ident: B20
  doi: 10.1200/JCO.2006.05.9055
– ident: B44
  doi: 10.1007/978-1-4615-4811-9_69
– ident: B22
  doi: 10.1007/978-1-62703-357-2_8
– ident: B34
  doi: 10.1038/bjc.1977.1
– ident: B53
  doi: 10.1056/NEJMoa0900386
– ident: B37
  doi: 10.1182/blood-2010-12-322909
– ident: B28
  doi: 10.1182/blood-2003-07-2577
– ident: B19
  doi: 10.1056/NEJMsa060185
– ident: B5
  doi: 10.1182/blood-2011-03-338707
– ident: B10
  doi: 10.1056/NEJMra1400972
– volume: 91
  start-page: 735
  year: 1998
  ident: B3
  publication-title: Blood
  contributor:
    fullname: Uckun FM
– ident: B39
  doi: 10.1182/blood-2007-02-070342
– ident: B25
  doi: 10.1200/JCO.1998.16.4.1270
– ident: B4
  doi: 10.1200/JCO.2014.59.1636
– ident: B11
  doi: 10.1200/JCO.1998.16.3.920
– ident: B32
  doi: 10.1016/S1470-2045(08)70314-0
– ident: B46
  doi: 10.1016/S0140-6736(98)11079-6
– ident: B29
  doi: 10.1126/science.1102160
– ident: B42
  doi: 10.1111/bjh.12865
– ident: B51
  doi: 10.1182/blood-2015-09-670729
– ident: B41
  doi: 10.1200/JCO.1999.17.12.3745
– ident: B24
  doi: 10.1200/JCO.2005.03.426
– ident: B8
  doi: 10.1056/NEJM199806043382304
– ident: B45
  doi: 10.1080/10428194.2017.1397658
– ident: B7
  doi: 10.1200/JCO.1997.15.6.2222
– ident: B15
  doi: 10.1182/blood-2010-06-292615
– ident: B12
  doi: 10.1097/MOP.0000000000000171
– ident: B27
  doi: 10.1016/S0037-1963(03)00195-1
– ident: B36
  doi: 10.1038/leu.2009.262
– ident: B48
  doi: 10.1056/NEJMoa035091
– ident: B1
  doi: 10.1200/JCO.2011.37.8018
– ident: B23
  doi: 10.1200/JCO.1995.13.2.310
– ident: B55
  doi: 10.1182/blood-2017-04-778829
SSID ssj0014835
Score 2.6585493
Snippet Early intensification with methotrexate (MTX) is a key component of acute lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX intensification...
PURPOSEEarly intensification with methotrexate (MTX) is a key component of acute lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 2926
SubjectTerms Adolescent
Adult
Antimetabolites, Antineoplastic - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Asparaginase - administration & dosage
Child
Child, Preschool
Disease-Free Survival
Female
Humans
Infant
Leucovorin - administration & dosage
Male
Methotrexate - administration & dosage
ORIGINAL REPORTS
Polyethylene Glycols - administration & dosage
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - mortality
Young Adult
Title Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization
URI https://www.ncbi.nlm.nih.gov/pubmed/30138085
https://search.proquest.com/docview/2093313655
https://pubmed.ncbi.nlm.nih.gov/PMC6366301
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELbKkBBfEIy38iYjoSHUpTSJE6d8K92qwdJ1glbqt8hNHLUaS9GSIspf4ifw57iL7aQdQxp8iarUuVa6J_b5_NxzhLyKPTftCsYtLryOxVLPtgA3qSUgtLX9gAdu2WNpeOIfTdjHqTdtNH5tsJZWxawd_7iyruR_vAr3wK9YJfsPnq2Mwg34DP6FK3gYrtfyscoIYMi4gjf-m6pFVGrFWJ-NOfHybW71UGUDqa7FvDW2YP8pkarTi5EkEK7BocsZRNGo3RrK1Zk8XwhFlMvLxwamBMVYLpP8oyxW-k0qn9XrhWGHuaw1xJ7UxYX8DlFs6xP8h-W5rvX8SyBcFWcutcU6F5TptiGfC-Se1mlaCLtzwxA-XmBPky_rulLtABb7RBWqDWGbLs7y-aKyqSlG70tVqnAz6WGXCrSa_ir1RO0AvriS-DUzuZJS0YjViRQ9L3cdf2ONhxiHXbl-OKo1dn-EpL-gzXmbO16nXisNP-BkFA0mYRiND6fjG-QmqjBi44aDD8fVERaD2Fafi4PVt5dtbsdBf2xuLnN0N4Ke8V1yRzuJ9hT07pGGzHbJraHmY-ySvVOlfL7ep-O6kC_fp3v0tNZEX98nPw1UqYEqBahSAygKMKElVKmCKkWo0gqqtIQq3YIqNVB9RzVQKQKVAlAru69zamBKS5hSA1O6CVO6BdMHZDI4HPePLN0nxIoZcwsLQnjbcQIR-yJ2eBzAtOTIxI1TH8JtW3SZSAWXHT9hPAmc2HVxIPOlL2eMJUy4D8lOtszkY0JlLOM06QpbpDYqCQoHnvSZhHWdOZJ5TfLGeC36quRgItxGO3gm3B9F6OGI8wg93CQvjVsjmLPxIE5kcrnKYVTXdZFfCvYeKTdX1lykDsA-qEn4FgCqAagHv_1NtpiXuvC-C9uHjv3kGr_7lNyuX6tnZKe4WMnnEF0Xsxclin8DSbzZEw
link.rule.ids 230,314,780,784,885,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improved+Survival+for+Children+and+Young+Adults+With+T-Lineage+Acute+Lymphoblastic+Leukemia%3A+Results+From+the+Children%27s+Oncology+Group+AALL0434+Methotrexate+Randomization&rft.jtitle=Journal+of+clinical+oncology&rft.au=Winter%2C+Stuart+S&rft.au=Dunsmore%2C+Kimberly+P&rft.au=Devidas%2C+Meenakshi&rft.au=Wood%2C+Brent+L&rft.date=2018-10-10&rft.eissn=1527-7755&rft.volume=36&rft.issue=29&rft.spage=2926&rft.epage=2934&rft_id=info:doi/10.1200%2FJCO.2018.77.7250&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon